A5047167196- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Virus-based gene therapy research
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Advancements in Semiconductor Devices and Circuit Design
- Reproductive System and Pregnancy
- Nanowire Synthesis and Applications
- Renal Transplantation Outcomes and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Biomedical Ethics and Regulation
Hospital Clínic de Barcelona
2017-2024
Areté Associates (United States)
2023
Fundació Clínic per a la Recerca Biomèdica
2022
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2022
Universitat de Barcelona
2022
Chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most them disease. Therefore, new therapeutic strategies are clearly needed. Here, we report comprehensive study comparing engineered either expressing second-generation CAR (CAR-T19) or secreting CD19/CD3-targeting bispecific...
The presence of donor‐specific antibodies (DSA), mainly against HLA, increases the risk allograft rejection. Moreover, antibody‐mediated rejection (ABMR) remains an important barrier to optimal long‐term outcomes after solid organ transplantation. development chimeric autoantibody receptor T lymphocytes has been postulated for targeted therapy autoimmune diseases. We aimed develop a DSA desensitization and ABMR, generating cells with HLA antibody (CHAR) that specifically eliminates...
Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Chronic lymphocytic leukemia (CLL) small lymphoma (SLL) remain incurable, despite advances in treatment. Moreover, patients (pts) with Richter's transformation (RT) have a poor prognosis limited treatment options. CD19-directed CAR-T therapy improved survival for pts broad range of B-cell malignancies. trials CD19 CAR-Ts shown promising antitumor responses CLL SLL, or without RT. However, no cell therapies...
<div>Abstract<p>Chimeric antigen receptor (CAR)–modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most them disease. Therefore, new therapeutic strategies are clearly needed. Here, we report comprehensive study comparing engineered either expressing second-generation CAR (CAR-T19) or secreting...
<div>Abstract<p>Chimeric antigen receptor (CAR)–modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most them disease. Therefore, new therapeutic strategies are clearly needed. Here, we report comprehensive study comparing engineered either expressing second-generation CAR (CAR-T19) or secreting...
Supplementary Data from Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
Supplementary Data from Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
Introduction: T cell immunotherapy using Chimeric Antigen Receptors (CARs) to generate tumor antigen-specific effector cells has achieved excellent results in anti-leukemic clinical trials, and a broader appraisal, promising immunotherapeutic results. A major problem solid organ transplantation is the presence recipient of donor specific antibodies, which preclude success transplant due associated high risk antibody-mediated rejection. Methods: we hypothesize that CAR (chimeric antigen...